The most common grade @ or worse adverse events in the olaparib group were fatigue ( in ten -LSB- @ % -RSB- patients in the olaparib group vs four -LSB- @ % -RSB- in the placebo group ) and anaemia ( seven -LSB- @ % -RSB- vs one -LSB- < @ % -RSB- ) .